ライフサイエンスコーパス: anticancer agent

1 s for safer dosing of this widely prescribed anticancer agent.

2 gene under current investigation as a novel anticancer agent.

3 rest in the potential use of metformin as an anticancer agent.

4 me inhibitor with desirable properties as an anticancer agent.

5 29 that potentially strengthen its use as an anticancer agent.

6 genetic protein 4 (BMP4) has potential as an anticancer agent.

7 n demonstrated to have potent activity as an anticancer agent.

8 PC is a natural pigment with potential as an anticancer agent.

9 days after adjudication) for the index oral anticancer agent.

10 ing its in vivo efficacy as a potential lead anticancer agent.

11 (HCT-116 colon cancer xenograft mouse model) anticancer agent.

12 Doxazolidine (doxaz) is a new anthracycline anticancer agent.

13 It also is in clinical trials as an anticancer agent.

14 explored the potential of stauprimide as an anticancer agent.

15 mpound of profound interest as a prospective anticancer agent.

16 nano-oral delivery system for this promising anticancer agent.

17 dicine has gained approval as a new class of anticancer agent.

18 rol (RES) has been studied extensively as an anticancer agent.

19 a styryl benzylsulfone, is a phase III stage anticancer agent.

20 serve as companion diagnostics for targeted anticancer agents.

21 l formulations of TPT and other weakly-basic anticancer agents.

22 erable interest as potential chemopreventive anticancer agents.

23 efficacious and nontoxic PAI-1 inhibitors as anticancer agents.

24 luable opportunities for rapid assessment of anticancer agents.

25 uinolinones was synthesized and evaluated as anticancer agents.

26 has the potential to enhance the efficacy of anticancer agents.

27 of direct Ras inhibitors as a novel class of anticancer agents.

28 ent a new class of potent microtubule-active anticancer agents.

29 cting compounds may represent novel powerful anticancer agents.

30 on the future development of these effective anticancer agents.

31 TH1 in general as a promising novel class of anticancer agents.

32 f histone deacetylase inhibitors (HDACIs) as anticancer agents.

33 adjudicated prescription for any of 38 oral anticancer agents.

34 exhibit reduced Bim levels and resistance to anticancer agents.

35 a-2) increased sensitivity to platinum-based anticancer agents.

36 inhibitors are gaining interest as potential anticancer agents.

37 oping specific Cdc20 inhibitors as effective anticancer agents.

38 ir immunogenic capacity as novel and dynamic anticancer agents.

39 e ProTide approach to generate promising new anticancer agents.

40 opment of glutamine metabolism inhibitors as anticancer agents.

41 a response mechanism to metabolic stress and anticancer agents.

42 y of various types of therapeutics including anticancer agents.

43 with respect to the development of potential anticancer agents.

44 m of action for PEITC and other ROS-inducing anticancer agents.

45 of alternate oral, injectable, or infusible anticancer agents.

46 a previously unpursued route for developing anticancer agents.

47 stress and contributes to resistance against anticancer agents.

48 nstrated mixed outcomes regarding statins as anticancer agents.

49 gy for development of specific and effective anticancer agents.

50 en prepared as a new chemotype for potential anticancer agents.

51 r sensitivities and resistance mechanisms to anticancer agents.

52 ork synergistically to create more effective anticancer agents.

53 a first step toward a new class of potential anticancer agents.

54 azones (BpT) class, show marked potential as anticancer agents.

55 spliceosome-modulating activity as potential anticancer agents.

56 us has become an attractive target for novel anticancer agents.

57 position 2 of the indole were synthesized as anticancer agents.

58 ce of targeting ERRalpha with antagonists as anticancer agents.

59 size, indicating their in vivo potential as anticancer agents.

60 tothecin and a variety of other DNA-damaging anticancer agents.

61 any type of DSB, including those induced by anticancer agents.

62 analogues have significant potential as new anticancer agents.

63 r the use of cell surface NCL antagonists as anticancer agents.

64 select patients for treatment with specific anticancer agents.

65 isen in developing Na,K-ATPase inhibitors as anticancer agents.

66 ms of RCC provide specific targets for novel anticancer agents.

67 toposide are widely used effective cytotoxic anticancer agents.

68 t of farnesyltransferase inhibitors as novel anticancer agents.

69 unds are members of a promising new class of anticancer agents.

70 t response and inform the development of new anticancer agents.

71 ligands with the aim to obtain multitargeted anticancer agents.

72 inct from that of these clinically validated anticancer agents.

73 rotects normal tissues during treatment with anticancer agents.

74 Autophagy mediates resistance to various anticancer agents.

75 have received comprehensive investigation as anticancer agents.

76 to quantify tumor changes during exposure to anticancer agents.

77 osomal delivery of poorly soluble, ionizable anticancer agents.

78 functions and can be developed as potential anticancer agents.

79 otubules, is a target for the development of anticancer agents.

80 able preclinical stratification schemata for anticancer agents.

81 s good candidates for further development as anticancer agents.

82 several distinct gold-containing indoles as anticancer agents.

83 el class of compounds that have potential as anticancer agents.

84 tors (FTIs and GGTIs) as chemical probes and anticancer agents.

85 meet safety and efficacy criteria for use as anticancer agents.

86 very and biological evaluations of PACMAs as anticancer agents.

87 compounds represent a new potential class of anticancer agents.

88 soform, and this may limit their efficacy as anticancer agents.

89 eudolaric acid B (PAB) holds promise for new anticancer agents.

90 inhibitors, potential anti-inflammatory and anticancer agents.

91 able core for optimization to identify novel anticancer agents.

92 tunity for endothelial-specific targeting of anticancer agents.

93 he development of these rigidin analogues as anticancer agents.

94 temic multi-delivery of poorly water soluble anticancer agents.

95 lysates for the early stage of apoptosis or anticancer agents.

96 as a potential target for the development of anticancer agents.

97 - and crinine-type alkaloids show promise as anticancer agents.

98 a useful structure for the generation of new anticancer agents.

99 These processes are targets of many anticancer agents.

100 of water-soluble and/or poorly water-soluble anticancer agents.

101 cumulate in DNA following treatment with the anticancer agents 5-fluorouracil and 5-fluorodeoxyuridin

102 and high drug encapsulation is desirable for anticancer agents, a mechanistic understanding is requir

103 ain permeability of two drugs, including the anticancer agent acivicin.

104 analysis of the direct effect of widely used anticancer agents (aclarubicin, ICRF-193, VM26, doxorubi

105 to DNA gyrase inhibition and suggests other anticancer agents act similarly.

106 tructure classes were evaluated as potential anticancer agents against human cancer cells from variou

107 they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma.

108 reversible proteasome inhibitor as potential anticancer agents against solid tumors.

109 ed the activity of ISC-4 and 19 FDA-approved anticancer agents, alone or in combination, against the

110 l-asparaginase (l-ase) is an anticancer agent also harboring glutaminase activity.

111 Conjugates bearing the anticancer agents aminohexylgeldanamycin (AHGDM), doceta

112 Our findings show that hSGZ is an effective anticancer agent and a potential candidate for clinical

113 s study illuminates the function of an early anticancer agent and suggests an intersection with ongoi

114 he chemotherapeutic drug Taxol, an important anticancer agent and the only known stabilizer that redu

115 erlying mechanism of action of aspirin as an anticancer agent and, based on the rapid metabolism of a

116 NAP have been suggested as immunotherapeutic anticancer agents and adjuvants for vaccination but with

117 ecent research on other poorly water-soluble anticancer agents and delivery of drug combinations (i.e

118 ied; they are now used in ex vivo studies of anticancer agents and early detection.

119 es are nanocarriers for poorly water-soluble anticancer agents and have advanced paclitaxel (PTX) to

120 udies that have expanded CTCs for testing of anticancer agents and how these approaches might be used

121 e therapeutic utility of GSTO1 inhibitors as anticancer agents and identify the novel cellular pathwa

122 g the administration of different classes of anticancer agents and in all cases observed that the mod

123 hat SIRT2-selective inhibitors are promising anticancer agents and may represent a general strategy t

124 -directed intraperitoneal targeting of other anticancer agents and nanoparticles using peptides and o

125 A wide spectrum of drugs, such as anticancer agents and steroids, are known P-gp substrate

126 ween the mechanisms of action of these novel anticancer agents and the imaging appearance of tumor re

127 orrelation between sensitivity to alkylating anticancer agents and topoisomerase inhibitors.

128 a bone targeting ligand, doxorubicin as the anticancer agent, and either an acid-sensitive bond (1)

129 ally important antibiotics, antifungals, and anticancer agents are actually present in the soils of N

130 Many of the molecules targeted by anticancer agents are also expressed in ocular tissues.

131 oside phosphonates as potential antiviral or anticancer agents are compiled.

132 These novel anticancer agents are critically discussed by the author

133 e syntheses of tetrasubstituted olefin-based anticancer agents are described.

134 Moreover, because the latest generations of anticancer agents are founded on biological mechanisms,

135 , providing a rationale for repurposing this anticancer agent as an Alzheimer's disease (AD) therapeu

136 ll most probably emerge for newly discovered anticancer agents as well.

137 enal transplantation, and of rapamycin as an anticancer agent, as well as from experimental studies.

138 d with paclitaxel, a microtubule-stabilizing anticancer agent, as well as with 6-coumarin, a fluoresc

139 implications); and there are highly specific anticancer agents available that effectively modulate th

140 While demonstrated to be effective anticancer agents, B-Raf or MEK inhibitors have also bee

141 We previously developed a series of anticancer agents based on cyclooxygenase-2 (COX-2) inhi

142 Anticancer agents based on haloacetic acids are develope

143 ized DNA-targeted platinum-containing hybrid anticancer agents based on metal-mediated amine-to-nitri

144 new 2-phenylindole derivatives as potential anticancer agents bearing the 3,4,5-trimethoxyphenyl moi

145 as promising probes of DNA structure and as anticancer agents because of their unique photophysical

146 ell death makes CDD a potentially attractive anticancer agent, because tumor resistance to the main m

147 vance to a broad spectrum of next-generation anticancer agents being developed by the medicinal inorg

148 The anticancer agent bortezomib inhibits the major peptidase

149 IR in vitro but also DNA-inducing cytotoxic anticancer agents, both in vitro and in vivo.

150 Doxorubicin is a highly effective anticancer agent but causes cardiotoxicity in many patie

151 e cancer cells are resistant to conventional anticancer agents but are sensitive to glycolytic inhibi

152 have demonstrated or predicted potential as anticancer agents, but a detailed structural basis for t

153 proliferation and is inhibited by promising anticancer agents, but its mode of action and the conseq

154 The anticancer agent camptothecin (CPT) is a DNA topoisomera

155 m, where the biologic effects of traditional anticancer agents can be delineated, prognostic and pred

156 n drug-mediated anticancer activity and that anticancer agents can be identified through their abilit

157 AIMS: Doxorubicin (DOX), a widely used anticancer agent, can cause an unpredictable cardiac tox

158 Despite the discovery of a large number of anticancer agents, cancer still remains among the leadin

159 Thus, novel anticancer agents capable of overcoming these intrinsic

160 sive efforts to target mutated RAS proteins, anticancer agents capable of selectively killing tumour

161 e) complexes have been shown to be promising anticancer agents, capable of overcoming major drawbacks

162 cules and their gene clusters, including the anticancer agent cinerubin B from Streptomyces sp. SPB74

163 sociated with the pattern of response to the anticancer agent cisplatin in human melanoma cells in vi

164 Strain-dependent delivery of the anticancer agents cisplatin and 7-ethyl-10-hydroxycampto

165 The platinum-based anticancer agents cisplatin, carboplatin, and oxaliplati

166 y a concise and stereoselective synthesis of anticancer agent combretastatin A-4.

167 Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduc

168 tecan (LMP400) and indimitecan (LMP776), two anticancer agents currently under investigation in a Pha

169 and cancer and also suggest the potential of anticancer agents designed to specifically neutralize ex

170 Clinical trials with other anticancer agents did not take into account the genetic

171 years, with the development of numerous oral anticancer agents, dosing options are arbitrarily and in

172 -dimethoxyflavone) has great potential as an anticancer agent, due to its specific chemopreventive ac

173 clinical translation of poorly water-soluble anticancer agents, especially for promising, rapidly eme

174 enium complexes are promising candidates for anticancer agents, especially NKP-1339 (sodium trans-[te

175 termini, and renders cells sensitive to the anticancer agent etoposide.

176 DF15) in glioblastoma cells treated with the anticancer agent fenofibrate.

177 Anticancer agent FL118 was recently identified in screen

178 t are currently under development for use as anticancer agents following the FDA approval of two HDAC

179 of EGFR protein abundance and as a potential anticancer agent for aneuploidy-driven colorectal cancer

180 ptide has potential to be developed as a new anticancer agent for intratumoral administration and is

181 cancers and that MLN4924 may be an effective anticancer agent for targeted ovarian cancer therapy.

182 inogenesis and its inhibition in sensitizing anticancer agents for killing of cancer cells.

183 ant approach for the development of targeted anticancer agents for ovarian cancer therapy, and they c

184 ensively prescribed as immunosuppressant and anticancer agents for several decades.

185 in situ generation of a triazole-containing anticancer agent from two benign components, opening up

186 reductase (RNR) is an attractive target for anticancer agents given its central function in DNA synt

187 The high market price of new anticancer agents has stimulated debate about the long-t

188 mmetric bis-benzimidazoles (BBZ) designed as anticancer agents have previously been shown to possess

189 -arylpyrrole (ARAP) derivatives as potential anticancer agents having different substituents at the p

190 Recent studies indicate that a class of anticancer agents, histone deacetylase (HDAC) inhibitors

191 drug conjugates hold considerable promise as anticancer agents, however, producing them remains a cha

192 These efforts include screening for novel anticancer agents, identifying novel therapeutic targets

193 ormin is currently considered as a promising anticancer agent in addition to its anti-diabetic effect

194 tion in vitro and in vivo and an efficacious anticancer agent in animal models of human cancers.

195 ze isoanabasine, preclamol, and niraparib-an anticancer agent in several clinical trials.

196 ltransferase Porcupine (Porcn) are candidate anticancer agents in clinical testing.

197 revent client maturation and show promise as anticancer agents in clinical trials.

198 al indenoisoquinolines have shown promise as anticancer agents in clinical trials.

199 otropic autophagy inhibitors may have use as anticancer agents in combination with conventional thera

200 The enhanced activity of these anticancer agents in combination with p28 was facilitate

201 upporting a role for monofunctional platinum anticancer agents in human cancer therapy.

202 e the therapeutic indices of different class anticancer agents in vivo.

203 iety of combinations of different classes of anticancer agents including small molecule drugs and bio

204 ollowing exposure to several stress-inducing anticancer agents, including ionizing radiation (IR), et

205 hat copes with DNA damage induced by several anticancer agents, including ionizing radiation and temo

206 tion of Rac hyperactivation to resistance to anticancer agents, including targeted therapies, as well

207 bocyclic analogues of an important series of anticancer agents inhibiting MDM2-p53 interactions.

208 he maximum tolerated dose of investigational anticancer agents is based on the cytotoxic chemotherapy

209 yrolactone analogues and their evaluation as anticancer agents is described.

210 Purpose The number of novel oral anticancer agents is increasing, but financial barriers

211 or subunit, MED12, in resistance to multiple anticancer agents is revealed by Huang et al.

212 of HOTAIR in pancreatic cancer resistance to anticancer agents is unknown.

213 the development of BXI(s) as a new class of anticancer agents is warranted and represents a novel st

214 Although TRAIL is considered a potential anticancer agent, it enhances tumor progression by activ

215 ones with camptothecin (CPT), a largely used anticancer agent, KuQs have been tested against Cisplati

216 ring resistance to many structurally diverse anticancer agents, leading to the phenomenon called mult

217 the microtubule lattice and is inhibited by anticancer agents like Taxol.

218 he real-world clinical effectiveness of oral anticancer agents may be diminished and may not emulate

219 ests that sorafenib, in addition to being an anticancer agent, may have potential to be developed as

220 a (PDA) cells by treatment with DNA-damaging anticancer agents (mitomycin C, oxaliplatin, cisplatin,

221 g lead for further development to obtain new anticancer agents of potential value for the treatment o

222 ly apparent that treatment with a variety of anticancer agents often is associated with adverse neuro

223 al proof of concept for a survivin-targeting anticancer agent, our work offers novel in silico screen

224 re is a steady increase in costs of patented anticancer agents over time.

225 insoluble drugs including the developmental anticancer agent PBS-1086.

226 omprehensive conformational analysis for the anticancer agent pironetin (1) was achieved by molecular

227 reticulum (ER) stress, as also found for the anticancer agent PRIMA-1(MET)(APR-246).

228 endazole, which may represent a new class of anticancer agents showing selective toxicity against can

229 received much attention as immunotherapeutic anticancer agents since the discovery that they harbor f

230 omatitis virus (VSV) are being considered as anticancer agents since they readily infect transformed

231 ivery of siRNA/miRNA combinations with other anticancer agents (siRNA/miRNA/pDNA/chemodrugs) to treat

232 nes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib

233 Reactive oxygen species (ROS)-inducing anticancer agents such as phenethylisothiocyanate (PEITC

234 is in human cancer and are targets for novel anticancer agents such as the Bcl-2 antagonists, ABT-263

235 iaryl (biaryl-benzenesulfonamides) as potent anticancer agents targeting both STAT3 and tubulin.

236 was illustrated by the short synthesis of an anticancer agent, TEI-9826.

237 sensitize cells to irradiation or to several anticancer agents tested.

238 his study, we present a small-molecule-based anticancer agent that acts by inhibiting dimerization of

239 ddition of iniparib, a novel investigational anticancer agent that does not possess characteristics t

240 Adriamycin (ADR) is an anticancer agent that increases oxidative stress in cell

241 ed apoptosis-inducing ligand) is a potential anticancer agent that induces apoptosis in a wide variet

242 ON01910.Na is a highly effective anticancer agent that induces mitotic arrest and apoptos

243 tosis-inducing ligand (TRAIL) is a promising anticancer agent that kills various tumor cells without

244 CPI-613 is a novel anticancer agent that selectively targets the altered fo

245 e a synergistic effect with methotrexate, an anticancer agent that targets purine biosynthesis.

246 pe compounds form a small distinct family of anticancer agents that are involved in both photo-activa

247 ted their potential as promising theranostic anticancer agents that can circumvent cisplatin resistan

248 ting PIP3 binding by PH domains as potential anticancer agents that can simultaneously interfere with

249 hes an integrated approach for testing novel anticancer agents that captures the inherent variability

250 compound would constitute a unique class of anticancer agents that could potentially have significan

251 a possible new route for the development of anticancer agents that could suppress KRAS expression.

252 r-chain n-3 MUFAs may be prototypes of novel anticancer agents that decrease the formation of PGE(2)

253 Several anticancer agents that form DNA adducts in the minor gro

254 cs have facilitated the development of novel anticancer agents that have decreased side effects and i

255 Recombinant immunotoxins (RITs) are potent anticancer agents that have produced many complete remis

256 Notably, unlike other anticancer agents that inhibit VEGF receptor signaling,

257 New anticancer agents that lead to improvements in time-to-e

258 t the 7-azaindenoisoquinolines are promising anticancer agents that merit further development.

259 r therapies involve the systemic delivery of anticancer agents that neither discriminate between canc

260 nia is a major side effect of a new class of anticancer agents that target histone deacetylase (HDAC)

261 Currently, there are no anticancer agents that target IRS1/2.

262 atment, and there is a clinical need for new anticancer agents that would selectively target MDR mali

263 affinity of ellipticine, a DNA-intercalating anticancer agent, the relative energetics between the A-

264 For two thirds of FDA approvals of anticancer agents, the requirement for predictive biomar

265 Due to the success of the platinum anticancer agents, there has been considerable interest

266 nts a potent strategy for using conventional anticancer agents to alter the tumor microenvironment an

267 The inability of anticancer agents to cross the blood-brain-barrier repre

268 YSAYPDSVPMMS) can be effective in delivering anticancer agents to such tumors.

269 barrier (BBB) prevents the transport of most anticancer agents to the central nervous system and rest

270 activation suppresses the proliferation and anticancer agent tolerance of HCC.

271 to monitor liposomal release kinetics of the anticancer agent topotecan (TPT) in physiological fluids

272 pes for anthracycline and taxane, two common anticancer agents use in clinics.

273 They are the target of anticancer agents used in the clinic such as anthracycli

274 etic precursor to the clinically significant anticancer agents vinblastine and vincristine.

275 of specialized metabolites that includes the anticancer agent vincristine, antimalarial quinine and n

276 Based on similarities to polyether anticancer agents we have further examined TDA's cytotox

277 rspective of using HTyr-derived compounds as anticancer agents, we have taken into account only studi

278 ng pursuit of CXCR4 antagonists as potential anticancer agents, we recently developed a potent, selec

279 ese cells, for the first time, two different anticancer agents were synthesized simultaneously intrac

280 cisplatin as the drug, since it is a potent anticancer agent which exhibits serious side effects due

281 nine, thereby providing strong resistance to anticancer agents which alkylate this position.

282 g conjugates (ADCs) are a promising class of anticancer agents which have undergone substantial devel

283 that serves both as an anti-inflammatory and anticancer agent, which differentially affects MDSC acti

284 es to use the toxin as a potent pH-selective anticancer agent, which predominantly targets highly pro

285 and complications associated with the novel anticancer agents will be summarized, since these are fr

286 oof-of-concept for ABDNAZ as a promising new anticancer agent with a favorable toxicity profile, eith

287 further investigation as a novel preclinical anticancer agent with application in the treatment of nu

288 tional p53 constitute potential nongenotoxic anticancer agents with a novel mode of action.

289 Acylfulvenes are a class of experimental anticancer agents with a unique repair profile suggestin

290 Clinical trials are underway combining anticancer agents with hydroxychloroquine (HCQ), but con

291 of 7-azaindenoisoquinolines resulted in new anticancer agents with improved Top1 inhibitory potencie

292 II) complexes are a novel class of promising anticancer agents with potential clinical significance.

293 model coupled tumor responses to individual anticancer agents with their mechanisms of action in viv

294 ase I (Top1) inhibitors are a novel class of anticancer agents with two compounds in clinical trials.

295 is focused on the benzoquinone ansamycins as anticancer agents, with several derivatives of the natur

296 any alternate oral, injectable, or infusible anticancer agent within 90 days.

297 ugmented the activity of clinically approved anticancer agents without added toxicity.

298 eered MSCs loaded with high concentration of anticancer agents without affecting their tumor-targetin

299 Taken together, TL-77 represents a promising anticancer agent worthy of further evaluation.

300 The clinical usefulness of these anticancer agents would be substantially augmented if AG